HAIM
ZVRA icon

Hunter Associates Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Hunter Associates Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,260
Closed -$119K – 282
2025
Q4 		$119K Hold
13,260
– – 0.02% 249
2025
Q3 		$126K Hold
13,260
– – 0.02% 255
2025
Q2 		$117K Hold
13,260
– – 0.02% 249
2025
Q1 		$99K Hold
13,260
– – 0.02% 244
2024
Q4 		$111K Hold
13,260
– – 0.02% 250
2024
Q3 		$92K Buy
+13,260
New +$90K 0.01% 254

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Hunter Associates Investment Management's ZVRA Position: Q1 2026 in Review

Hunter Associates Investment Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 13,260 shares — an estimated $119K sold.

Hunter Associates Investment Management first reported a position in ZVRA in Q3 2024 and held it in 6 quarters. The position peaked at $126K in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Hunter Associates Investment Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hunter Associates Investment Management sold 13,260 Zevra Therapeutics shares in Q1 2026, an estimated $119K.
  • Hunter Associates Investment Management first reported a position in Zevra Therapeutics in Q3 2024 and held it in 6 quarters.
  • Hunter Associates Investment Management's Zevra Therapeutics position peaked at $126K in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Hunter Associates Investment Management's 13F filing for Q1 2026, filed 27 Apr 2026.